Larimar Therapeutics (LRMR) Competitors $4.86 -0.24 (-4.71%) Closing price 04:00 PM EasternExtended Trading$4.85 -0.01 (-0.25%) As of 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LRMR vs. STOK, TLRY, EVO, RCUS, NTLA, TRML, PHVS, XERS, GPCR, and CVACShould you be buying Larimar Therapeutics stock or one of its competitors? The main competitors of Larimar Therapeutics include Stoke Therapeutics (STOK), Tilray Brands (TLRY), Evotec (EVO), Arcus Biosciences (RCUS), Intellia Therapeutics (NTLA), Tourmaline Bio (TRML), Pharvaris (PHVS), Xeris Biopharma (XERS), Structure Therapeutics (GPCR), and CureVac (CVAC). These companies are all part of the "pharmaceutical products" industry. Larimar Therapeutics vs. Its Competitors Stoke Therapeutics Tilray Brands Evotec Arcus Biosciences Intellia Therapeutics Tourmaline Bio Pharvaris Xeris Biopharma Structure Therapeutics CureVac Stoke Therapeutics (NASDAQ:STOK) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment. Do analysts rate STOK or LRMR? Stoke Therapeutics currently has a consensus price target of $25.57, indicating a potential upside of 11.42%. Larimar Therapeutics has a consensus price target of $18.43, indicating a potential upside of 279.19%. Given Larimar Therapeutics' higher possible upside, analysts plainly believe Larimar Therapeutics is more favorable than Stoke Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stoke Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22Larimar Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings & valuation, STOK or LRMR? Larimar Therapeutics has lower revenue, but higher earnings than Stoke Therapeutics. Larimar Therapeutics is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStoke Therapeutics$199.89M6.29-$88.98M$0.8527.00Larimar TherapeuticsN/AN/A-$80.60M-$1.56-3.12 Does the media refer more to STOK or LRMR? In the previous week, Stoke Therapeutics had 2 more articles in the media than Larimar Therapeutics. MarketBeat recorded 3 mentions for Stoke Therapeutics and 1 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 1.91 beat Stoke Therapeutics' score of 1.25 indicating that Larimar Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Stoke Therapeutics Positive Larimar Therapeutics Very Positive Do insiders & institutionals have more ownership in STOK or LRMR? 91.9% of Larimar Therapeutics shares are owned by institutional investors. 9.5% of Stoke Therapeutics shares are owned by company insiders. Comparatively, 4.5% of Larimar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, STOK or LRMR? Stoke Therapeutics has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Comparatively, Larimar Therapeutics has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. Is STOK or LRMR more profitable? Stoke Therapeutics has a net margin of 26.25% compared to Larimar Therapeutics' net margin of 0.00%. Stoke Therapeutics' return on equity of 18.32% beat Larimar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Stoke Therapeutics26.25% 18.32% 15.48% Larimar Therapeutics N/A -62.92%-53.98% SummaryStoke Therapeutics beats Larimar Therapeutics on 11 of the 16 factors compared between the two stocks. Get Larimar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LRMR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LRMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LRMR vs. The Competition Export to ExcelMetricLarimar TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$402.30M$2.50B$5.65B$10.29BDividend YieldN/A56.32%5.68%4.61%P/E Ratio-3.1223.2875.8626.14Price / SalesN/A564.82515.95170.63Price / CashN/A174.1537.5661.52Price / Book1.815.1512.886.30Net Income-$80.60M$32.95M$3.29B$271.03M7 Day Performance13.55%0.15%-0.24%-0.13%1 Month Performance30.65%5.09%3.87%6.43%1 Year Performance-23.34%1.17%68.39%28.82% Larimar Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LRMRLarimar Therapeutics2.4122 of 5 stars$4.86-4.7%$18.43+279.2%-20.4%$402.30MN/A-3.1230Positive NewsHigh Trading VolumeSTOKStoke Therapeutics3.9125 of 5 stars$23.40-0.3%$25.57+9.3%+77.7%$1.29B$36.56M27.53100Positive NewsTLRYTilray Brands2.6389 of 5 stars$1.18+5.4%$1.94+64.2%-26.7%$1.23B$210.48M-0.512,842Gap DownEVOEvotec1.5894 of 5 stars$3.50+0.9%$5.40+54.3%+10.1%$1.23B$862.40M0.004,827Gap DownRCUSArcus Biosciences1.6314 of 5 stars$11.57+0.4%$21.14+82.7%-19.6%$1.23B$258M-3.65500Positive NewsNTLAIntellia Therapeutics4.4412 of 5 stars$11.57+1.3%$27.11+134.3%-17.3%$1.23B$52.86M-2.47600TRMLTourmaline Bio0.9382 of 5 stars$47.65+0.1%$45.65-4.2%+102.8%$1.22BN/A-13.8944Positive NewsPHVSPharvaris2.3302 of 5 stars$23.38+0.8%$34.00+45.4%+28.6%$1.21BN/A-6.9630XERSXeris Biopharma2.2834 of 5 stars$7.36-1.7%$7.08-3.8%+183.7%$1.21B$203.07M-35.05290Positive NewsGPCRStructure Therapeutics2.9886 of 5 stars$20.20-3.4%$75.71+274.8%-41.8%$1.20BN/A-19.24136Positive NewsCVACCureVac3.9751 of 5 stars$5.36+0.4%$6.83+27.5%+68.0%$1.20B$579.18M5.58880News CoveragePositive News Related Companies and Tools Related Companies Stoke Therapeutics Alternatives Tilray Brands Alternatives Evotec Alternatives Arcus Biosciences Alternatives Intellia Therapeutics Alternatives Tourmaline Bio Alternatives Pharvaris Alternatives Xeris Biopharma Alternatives Structure Therapeutics Alternatives CureVac Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LRMR) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Larimar Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Larimar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LRMR Stock Alerts